Agios Pharmaceuticals’ Post

NEW #MPN Session from #ASH23🩸 💬 This EXCLUSIVE discussion features leading experts Ruben Mesa, MD, Claire Harrison & Jean-Jacques Kiladjian, who discuss key updates in the #treatment and #management of #myeloproliferativeneoplasms (#MPNs) following the 65th ASH Annual Meeting and Exposition The experts cover a variety of topics, including #novelagents being explored in essential #thrombocythemia (ET), updates in the treatment of #polycythemiavera (PV), and novel combinations being evaluated in #myelofibrosis (MF) 🔦 Take a look 👉 https://lnkd.in/eXeXjSFj #HemOnc #MPNsm American Society of Hematology

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology

How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0

The American Journal of Hematology recently published the results of a phase II study of BTK inhibitor orelabrutinib in patients with ITP.  “The phase 2 study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP. Further investigation through larger, randomized, placebo-controlled trials is warranted to definitively confirm these findings and establish orelabrutinib as a valuable treatment option for ITP management，” said Professor Ming Hou, the leading PI. Read more: https://lnkd.in/eXSyjcVD Full paper is here: https://lnkd.in/evmzBApi

Today we presented real-world evidence evaluating a CD-19-directed antibody for relapsed or refractory DLBCL at the American Society of Hematology Annual Meeting. Check out the abstract to learn more. #ASH23 https://bit.ly/47KZjkM

Excited to share preliminary data from the Century Therapeutics, Inc ELiPSE-1 trial and a case study of a patient who maintained a CR while receiving four 28 day cycles of CNTY-101 at the lowest dose level. CNTY-101 is engineered with six precision edits, including ALLO-EVASION technology to enable repeat dosing. Importantly, this patient's first two cycles included lymphodepletion while the next two did not. No pre-existing or induced anti-drug antibodies were detected and each infusion demonstrated comparable kinetics. These early results are encouraging for both oncology and non-oncology indications, where the side effect profile of lymphodepletion may be prohibitive. #ipsc #celltherapy #geneediting #oncology #autoimmune

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology

Discover the latest developments in myeloma research from the Annual American Society of Hematology meeting. Clinical trial investigators share their abstract presentations from ASH delving deep into the key research takeaways. Watch Now: https://lnkd.in/gaawhHcq #ASH23

ISB 1342, Ichnos’ CD38 x CD3 T-cell engager for relapsed/refractory multiple myeloma, is highlighted on the cover of the American Society of Hematology's journal, Blood. In this latest print edition of the journal, you’ll find our latest research article, Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma: https://lnkd.in/ezwyFBUE

In this roundtable discussion at the 65th American Society of Hematology Annual Meeting & Exposition, Drs. Hana Safah, Jamile Shammo, Andrew Brunner, and Tiffany Tanaka share their outlook for the future of myelodysplastic syndromes research and treatments. Watch here: https://buff.ly/4aV7vB8